In another move to strengthen and broaden its immuno-oncology pipeline, Novartis has in-licensed Xoma’s anti-transforming growth factor-beta (TGFb) antibody programme in a deal potentially worth up to US$517 M, including an upfront payment of US$37 M. For struggling Xoma, which lost 77% of its market value in July 2015 when its lead asset gevokizumab failed to meet its primary endpoint in a Phase III trial in Behcet's disease uveitis, the deal provides a much-needed cash injection as well as debt relief.